Key risks
- PE of 38.47 is materially elevated relative to typical pharma valuations; verify earnings growth trajectory to justify the premium.
- Operating margins of 14.9% average with quarterly range of 10.78%–15.53% indicate operational inconsistency and vulnerability to cost or price pressure.
- FII shareholding at 0.34% is negligible, suggesting barriers to foreign capital flows or investor-perception gaps; verify reasons.
- Generic pharmaceutical competition and regulatory pricing pressure in India are sector headwinds; verify product positioning and pricing sustainability.
Generated analysis · source review pending